Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis

A multi-institutional study in Japan

Tomohiro Kubota, Syuji Takei, Masaki Shimizu, Junko Yasumura, Yasuo Nakagishi, Toshitaka Kizawa, Masato Yashiro, Hiroyuki Wakiguchi, Yuichi Yamasaki, Yoshifumi Kawano

Research output: Contribution to journalArticle

Abstract

Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - Dec 22 2017

Fingerprint

Juvenile Arthritis
Biological Factors
Blood Sedimentation
Japan
Matrix Metalloproteinase 3
Therapeutics
Odds Ratio
Confidence Intervals

Keywords

  • Biologic agents
  • DAS28-ESR
  • juvenile idiopathic arthritis
  • polyarticular type
  • treat to target

ASJC Scopus subject areas

  • Rheumatology

Cite this

Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis : A multi-institutional study in Japan. / Kubota, Tomohiro; Takei, Syuji; Shimizu, Masaki; Yasumura, Junko; Nakagishi, Yasuo; Kizawa, Toshitaka; Yashiro, Masato; Wakiguchi, Hiroyuki; Yamasaki, Yuichi; Kawano, Yoshifumi.

In: Modern Rheumatology, 22.12.2017, p. 1-6.

Research output: Contribution to journalArticle

Kubota, Tomohiro ; Takei, Syuji ; Shimizu, Masaki ; Yasumura, Junko ; Nakagishi, Yasuo ; Kizawa, Toshitaka ; Yashiro, Masato ; Wakiguchi, Hiroyuki ; Yamasaki, Yuichi ; Kawano, Yoshifumi. / Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis : A multi-institutional study in Japan. In: Modern Rheumatology. 2017 ; pp. 1-6.
@article{43700604aa894e1191741b57b6868d31,
title = "Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan",
abstract = "Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75{\%}) was 40 months (median, range 24–119) and switching group (8 patients; 25{\%}) was 9.5 months (median, 6–18). Markers [odds ratio (95{\%} confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5{\%}; specificity, 87.5{\%}). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.",
keywords = "Biologic agents, DAS28-ESR, juvenile idiopathic arthritis, polyarticular type, treat to target",
author = "Tomohiro Kubota and Syuji Takei and Masaki Shimizu and Junko Yasumura and Yasuo Nakagishi and Toshitaka Kizawa and Masato Yashiro and Hiroyuki Wakiguchi and Yuichi Yamasaki and Yoshifumi Kawano",
year = "2017",
month = "12",
day = "22",
doi = "10.1080/14397595.2017.1415628",
language = "English",
pages = "1--6",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis

T2 - A multi-institutional study in Japan

AU - Kubota, Tomohiro

AU - Takei, Syuji

AU - Shimizu, Masaki

AU - Yasumura, Junko

AU - Nakagishi, Yasuo

AU - Kizawa, Toshitaka

AU - Yashiro, Masato

AU - Wakiguchi, Hiroyuki

AU - Yamasaki, Yuichi

AU - Kawano, Yoshifumi

PY - 2017/12/22

Y1 - 2017/12/22

N2 - Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.

AB - Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p = .219], ESR [1.00 (0.78–1.30), p = .998], and DAS28-ESR [13.9 (2.08–409.82), p = .035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.

KW - Biologic agents

KW - DAS28-ESR

KW - juvenile idiopathic arthritis

KW - polyarticular type

KW - treat to target

UR - http://www.scopus.com/inward/record.url?scp=85039865192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039865192&partnerID=8YFLogxK

U2 - 10.1080/14397595.2017.1415628

DO - 10.1080/14397595.2017.1415628

M3 - Article

SP - 1

EP - 6

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -